GB-0669
AI-designed monoclonal antibody for durable neutralization of SARS-CoV-2.
Executive Summary
GB-0669 is a pioneering monoclonal antibody developed by Generate Biomedicines, leveraging its advanced machine learning-powered generative biology platform. This therapeutic candidate is specifically designed to target a conserved region of the SARS-CoV-2 spike protein, aiming to provide durable neutralization against the virus. The innovative approach of using AI to design antibodies allows for the creation of novel protein molecules with precise functional programming. Currently in Phase 1 clinical trials, GB-0669 has demonstrated promising "First-in-Human Results" showing durable neutralization. By focusing on conserved regions, the antibody seeks to offer broad protection not only against existing SARS-CoV-2 variants but also potentially against future viral threats. This represents a significant step in applying generative AI to accelerate the discovery and development of next-generation biologics.
Use Cases
- Treatment of acute SARS-CoV-2 infections.
- Prophylaxis against SARS-CoV-2 infection, particularly for vulnerable populations.
- Addressing emerging SARS-CoV-2 variants through targeting conserved viral regions.
- Potential for broader protection against future coronaviral threats.
Features
Intelligence
- AI-Designed Antibodies: Utilizes a generative biology platform to design novel antibodies like GB-0669, targeting specific biological functions and regions.
- Durable Neutralization: Engineered to provide long-lasting neutralization against viral threats by targeting conserved regions of the spike protein.
Technical Specifications
AI/ML Stack
- Generative AI
- Machine Learning
- Chroma (generative model)
About Generate Biomedicines
Generate Biomedicines is a therapeutics company pioneering generative biology at the intersection of machine learning, biological engineering, and medicine to create breakthrough medicines. It operates as a developer of a machine learning-powered biomedicines platform with the potential to generate new drugs across a wide range of biologic modalities.